Stonepine Capital Management LLC Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Stonepine Capital Management LLC purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 110,000 shares of the company’s stock, valued at approximately $362,000. Eton Pharmaceuticals makes up approximately 0.3% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. Stonepine Capital Management LLC owned approximately 0.43% of Eton Pharmaceuticals at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Opaleye Management Inc. grew its stake in shares of Eton Pharmaceuticals by 4.1% in the fourth quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock valued at $11,081,000 after buying an additional 99,617 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $3,095,000. Westside Investment Management Inc. lifted its holdings in shares of Eton Pharmaceuticals by 2.0% during the second quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after buying an additional 11,440 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Eton Pharmaceuticals by 13.7% in the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after purchasing an additional 18,898 shares during the period. Finally, Thompson Siegel & Walmsley LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $420,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. purchased 57,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average price of $4.65 per share, with a total value of $267,375.00. Following the transaction, the insider now owns 2,660,000 shares in the company, valued at $12,369,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.89% of the stock is currently owned by insiders.

Eton Pharmaceuticals Price Performance

ETON stock opened at $6.00 on Tuesday. The stock has a market cap of $154.15 million, a price-to-earnings ratio of 150.00 and a beta of 1.30. The company has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $3.85. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $6.25.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The firm had revenue of $9.07 million for the quarter, compared to the consensus estimate of $10.00 million. On average, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.15 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday, September 4th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.